FluoGuide A/S develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Preclinical studies have demonstrated the potential of FG001 to vastly improve the likelihood of performing radical surgery (removal of all cancer) and thereby improving outcome and survival. FluoGuide is initially focused on glioblastoma (brain tumor) but the Company plan to expand its business to other solid tumors. Market launch of FG001 in a first country is expected in 2022/2023.
I am very excited about this new position being both professionally challenging and with a great potential for the patients with cancer
We are very pleased to have Dorthe joining the development team at FluoGuide. We will continue to expand the team as we advance FG001 through clinical development to approval
The grant of €2.5 million is an important achievement that will support the transformation of FluoGuide into a late clinical stage company with a pipeline of products
I am very excited about the recognition from EIC selecting FluoGuide as a top innovator within the EU. This is also an acknowledgement of all the hard work undertaken over the last decade by my research team at Rigshospitalet and University of Copenhagen where we together with collaborators developed the technology on which FluoGuide was build
The entire FluoGuide team is working hard to capture the enormous potential of the Company to help patients and benefit shareholders. We are extremely proud of the recognition from the independent IPO Guide – awarding FluoGuide as Best IPO in 2019
Our enthusiasm thus far has been quite high, but Q1 increased our optimism even further. We look forward to the next quarters and to delivering on many significant milestones
Completing a comprehensive pre-clinical toxicity program including species qualification and submitting a clinical trial appplication in less than 9 months is very fast compared to industry standard
I am pleased to see the clean outcome of the pre-clinical program, which predicts a low risk of safety findings in the human clinical trial
We prioritize to create long term shareholder value by maximizing the outcome for surgery of patients with cancer as much and as fast as possible
Sweden is one of the most competitive IPO markets in Europe
The entire FluoGuide team is working hard to capture the enormous potential of the Company to help patients and benefit shareholders. We are extremely proud of this recognition from the independent IPO Guide
Our IPO Guide aims to investigate and analyze all listings for the benefit of investors. Feedback from the market is that the IPO Guide provides an incentive for higher quality – it provides a mechanism for bad apples to be exposed and the best examples to be praised
As the company's advisor since the IPO, we have followed FluoGuide closely and we are obviously extremely happy with the progress the company has made. In a relatively short time, FluoGuide has not only achieved its stated goals but also achieved them in a shorter time than projected. We know how ambitious FluoGuide is and are not surprised by the awards they have received
It is great to see how our scientific work with the support from Innovation Fund Denmark is developed to benefit cancer patients and taken further through an IPO to build a Scandinavian based company to the benefit of society
We are very pleased with our development and our shareholders’ interest in FluoGuide. The proceed from the warrants will contribute to transform FluoGuide from a pre-clinical organization now into a late clinical-phase company with a pipeline of indications and products during 2021
As stated before, we believe FluoGuide has enormous potential and we look forward to deliver on this to shareholders and patients
I am happy to see that we are able to deliver tangible results from our Grand Solutions Grant from Innovation Fund Denmark
We are now focused on providing scientific rationale for selecting and prioritizing the product opportunities, so we in the future will be able to improve treatment of as many cancer patients as possible
We are happy that the initial data from our clinical proof-of-concept study in glioblastoma for FG001 and the research data on new compounds will be available later this year
With this agreement we have secured the option to broaden our pipeline of products that will allow us to fully explore the ample potential that lies in uPAR-targeted optical imaging
I would like to thank all shareholders – new and from the IPO for the strong confidence in our business, our product and us. Together with an extraordinary team, I am looking forward to transform FluoGuide from a pre-clinical company into a phase III company with a pipeline of indications and products during 2021 - a very exciting year ahead
Based on the combination of successful production of the compound, pre-clinical safety data and consistently positive preclinical data on FG001 lightening glioblastomas, we now strongly believe it is no longer a question of whether FG001 will work in humans but rather how well it will perform
We are happy that FG001 is showing such promising momentum and that we can accelerate the clinical development. Through this investment we will secure funds that will both shorten the time to market for FG001 as well as enable us faster to develop a portfolio of indications and products
This is a great opportunity for FluoGuide to simultaneously broaden the owner base and raise new capital for an accelerated commercialization of FG001. The Board of Directors considers it advantageous for FluoGuide and existing shareholders to attract such knowledgeable industry investors that gives great condition for the future
We are now producing the FG001 in a quality for use in patients. We have everything in place and the surgeons are ready to begin testing the new technology. That way, they can become even better at what they are doing already - removing cancer and thus hopefully healing patients.
We are delighted that the safety study is now initiated and look forward to an exciting 2020. We would of course have preferred to deliver the first result from the clinical study in Q2 2020 but prefer to temporal shift three months now to minimise risk of a delay at a later stage that could have seriously affected our commercial milestones and budget
We are happy to announce that FluoGuide has now been awarded this important product patent on FG001 in Europe. It is an exciting start of 2020 being an important year for FluoGuide
I am very pleased that we now have established a supply chain for FG001 and that we have transferred the process to vendors who can manufacture it for human use. We have made the first larger scale batch in an amount that could serve early commercialization through compassionate use sale. This is according to plan which we consider great news and a major de-risking for first proof-of-concept results from a clinical study in 2020
We are very happy to see another series of promising data now obtained with FG001 and demonstrating the relevance of uPAR target product for a number of different cancer types
FG001 again showed that it lightens up human brain cancer and an optimal dose giving a high visibility and contrast to the background has been now been determined as an important information for designing the forthcoming clinical study
Yet another equipment for NIR imaging was used used together with FG001 in this study compared to the data presented yesterday on FG001 guided surgical resection of metastatic pancreatic cancer. This illustrates the important fact that FG001 is compatible with a broad range of types of equipment.
Translated to humans, this result indicates that half of the patients undergoing traditional white light surgery would have been sent home with a metastasis that could have been detected and removed using FG001
We are very excited to bring this promising product forward with the potential to help improve the surgical outcome for patients with pancreatic cancer
We are very pleased with the successful IPO and to see that the potential of uPAR as target for guiding cancer surgery is unfolding earlier than expected as exemplified with the two presentations at WMIC
I am very pleased that promising data on the benefit of FG001 in glioblastoma and pancreatic cancer have been selected for presentation at WMIC, an important society within molecular imaging and surgical guidance. Optical targeting of uPAR is likely to become of benefit to patients and surgeons in several cancer indications and this presentation is an important event to highlight the technology’s potential.
We are very happy that this promising data has been selected for presentation at WMIC, an important society within molecular imaging and surgical guidance. Optical targeting of uPAR is likely to become of benefit to patients and surgeons in several cancer indications and this presentation is an important event to highlight the technology’s potential.
We are positive that presentation of the data will contribute to the understanding that uPAR is a highly interesting target and can lead FluoGuide to a leading position in the field of guiding cancer surgery
We are happy to see another series of promising data now obtained with a product that has been produced under higher quality standards and closer to what will be used in the clinical trial in patients scheduled for next year. This will be an important milestone for the team that has been working hard on FG001 for years
I am very pleased that we are now more than 1,000 shareholders working together to transform cancer surgery by lighting up the cancer for the benefit of patients and society in general. We have initiated the critical development activities needed for announcing the first clinical result for FG001 in second half of 2020 as planned.
I am very pleased that we are now approx. 1,500 shareholders working together to increase the precision in cancer surgery to the benefit of patients and society in general. We value the trust that we have been shown and we will work hard on delivering on the milestones advancing our first product FG001 towards the market and broad clinical use
We have seen a strong and broad interest and we’ve boarded our first institutional investor, which is a Danish institutional investor under the regulation of Danish Finanstilsynet, who has become shareholder with a long-term interest. This is very important for FluoGuide and the company’s shareholders
